Clinical Trials Sponsored by Fujian Cancer Hospital

Total 10606 results

Fujian Cancer Hospital

Recruiting

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Colorectal Cancer | Immunotherapy

China
Fujian Cancer Hospital

Recruiting

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer

Colorectal Cancer Stage II | Colorectal Cancer Stage III
Fujian Cancer Hospital

Not yet recruiting

POF Versus FOLFOX Plus IP Paclitaxel in AGC

Gastric Cancer
Fujian Cancer Hospital

Recruiting

A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

Gastric Cancer Stage III

China
Fujian Cancer Hospital

Enrolling by invitation

Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

EGFR/ ALK-negative Advanced NSCLC

China
Fujian Cancer Hospital

Enrolling by invitation

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Malignant Melanomas

China
Fujian Cancer Hospital

Enrolling by invitation

Tislelizumab as Cross-line Treatment for Advanced NSCLC

Advanced Non-small-cell Lung Cancer

China
Fujian Cancer Hospital

Withdrawn

Study of FMT Combined With Nivolumab in Gastric Cancer

Gastric Adenocarcinoma | Esophagus Adenocarcinoma | Esophagogastric Junction Adenocarcinoma

China
Fujian Cancer Hospital

Unknown

Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital

Completed

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

Malignant Neoplasm of Stomach Stage IV

China
Fujian Cancer Hospital

Withdrawn

Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma

Colorectal Adenocarcinoma

China
Fujian Cancer Hospital

Completed

Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration

Cancer Pain

China
Fujian Cancer Hospital

Completed

To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital

Unknown

Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain

Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naive
Fujian Cancer Hospital

Unknown

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Advanced Gastric Adenocarcinoma

China
Fujian Cancer Hospital

Unknown

Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens (ASGARD)

Advanced Metastatic Gastric Cancer
Fujian Cancer Hospital

Completed

Effects of Anesthesia on Tumor Immunity and Insulin Resistance During Perioperative Period

Cervical Cancer | Anesthesia | Carbohydrate | Tumor Immunity

China
Fujian Cancer Hospital

Unknown

Next-generation Sequencing in Gastrointestinal Cancer

Gastrointestinal Cancer

China
Fujian Cancer Hospital

Unknown

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

China
Fujian Cancer Hospital

Not yet recruiting

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

Immunotherapy Gastroesophageal Junction

China
Fujian Cancer Hospital

Not yet recruiting

Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

Cervical Cancer
Fujian Cancer Hospital

Recruiting

Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

Stage IIIA Hepatocellular Carcinoma

China
Fujian Cancer Hospital

Recruiting

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Carcinoma | Cervix Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

Hepatocellular Carcinoma
Fujian Cancer Hospital

Recruiting

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Colorectal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Colorectal Cancer
Fujian Cancer Hospital

Not yet recruiting

Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

Gastric Cancer
Fujian Cancer Hospital

Not yet recruiting

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Solid Tumor
Fujian Cancer Hospital

Not yet recruiting

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

Esophageal Cancer
Fujian Cancer Hospital

Not yet recruiting

Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines

Nasopharyngeal Carcinoma
Fujian Cancer Hospital

Not yet recruiting

the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology | The TNM (8th) Phase is IV | With EGFR Mutations | Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment | Male or Female | The Age of 18 Years Old or... and other conditions
Fujian Cancer Hospital

Recruiting

Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric Cancer

Surgery

China
Fujian Cancer Hospital

Not yet recruiting

Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Advanced Triple Negative Breast Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

Using Mini Program for Self-management VS Conventional Pharmaceutical Care for Cancer Pain

Cancer Pain
Fujian Cancer Hospital

Not yet recruiting

IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration

Cancer Pain

China
Fujian Cancer Hospital

Recruiting

Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study

Advanced Colorectal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer

Gastric Cancer
Fujian Cancer Hospital

Not yet recruiting

Study of the Apatinib Combine With POF Versus POF in Gastric Cancer

Gastric Adenocarcinoma | Advanced Cancer

China
Fujian Cancer Hospital

Withdrawn

Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain

Cancer Pains
Fujian Cancer Hospital

Unknown

Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma

Gastric Adenocarcinoma

China
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Fujian Cancer Hospital

Unknown

Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

Malignant Neoplasm of Stomach Stage II

China
Fujian Cancer Hospital

Unknown

Cognitive Dysfunction in Patients With Cancer Pain

Cognitive Dysfunction

China
Fujian Cancer Hospital

Unknown

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

Squamous Cell Carcinoma
Fujian Cancer Hospital

Withdrawn

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Metastatic Colorectal Cancer

China
Fujian Cancer Hospital

Unknown

Phase I Study of the Combination of Apatinib and POF

Gastric Adenocarcinoma

China
Fujian Cancer Hospital

Unknown

The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients

Breast Cancer | Angiogenesis
Fujian Cancer Hospital

Completed

Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma

Nasopharyngeal Cancer Recurrent

China

3

Subscribe